サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1798358

ブルキンサの世界市場

Brukinsa

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
ブルキンサの世界市場
出版日: 2025年08月26日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ブルキンサの世界市場は2030年までに7億7,680万米ドルに達する見込み

2024年に6億1,590万米ドルと推定されるブルキンサの世界市場は、2024～2030年の分析期間にCAGR 3.9%で成長し、2030年には7億7,680万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである急性リンパ性白血病は、CAGR 3.3％を記録し、分析期間終了時には5億1,670万米ドルに達すると予測されます。慢性リンパ性白血病セグメントの成長率は、分析期間中CAGR 5.4%と推定されます。

米国市場は1億6,780万米ドルと推定、中国はCAGR 7.1％で成長すると予測

米国のブルキンサ市場は2024年に1億6,780万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.1%として、2030年までに1億5,650万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.0%と予測されています。欧州では、ドイツがCAGR 2.3%で成長すると予測されています。

世界のブルキンサ市場- 主要動向と促進要因のまとめ

ブルキンサが血液悪性腫瘍治療のゲームチェンジャーとなった理由とは？

BeiGene社が開発した次世代のブルトン型チロシンキナーゼ（BTK）阻害剤であるブルキンサは、血液がん、特にマントル細胞リンパ腫（MCL）、慢性リンパ性白血病（CLL）、ワルデンシュトレーム・マクログロブリン血症（WM）患者に対する極めて重要な治療薬として急速に台頭してきました。BTKに対する高い選択性と、B細胞受容体のシグナル伝達経路を効果的に阻害する能力により、B細胞性悪性腫瘍に対する重要な武器となります。ブルキンサを際立たせているのは、イブルチニブなどの初期のBTK阻害剤に比べ、標的占有率が高く、組織浸透性が改善されているため、有効性が向上し、標的外副作用が少ないという、その良好な薬物動態プロファイルです。また、心房細動や出血などの治療を制限する有害事象の発生率も低く、特に高齢者やハイリスク患者にとってより忍容性の高い薬剤です。ブルキンサは、再発・難治性患者における高い奏効率や無増悪生存期間の改善など、強力な臨床試験成績に基づき、米国、中国、欧州連合（EU）において複数の薬事承認を取得しています。また、比較試験から多くのデータが得られつつあり、最前線の治療薬としての役割も注目されています。がん専門医によるブルキンサの価値に対する認識の高まりと、様々な臨床ガイドラインへの記載は、標的治療が従来の化学療法に急速に取って代わりつつある様々な血液がんに対する標準治療の再定義におけるブルキンサの重要性を強調しています。

ブルキンサの世界展開の原動力となる臨床試験の成果と規制当局の承認は？

ブルキンサの臨床的成功は、規制当局の承認を広く確保し、BTK阻害剤市場におけるトップランナーとしての地位を確立するのに役立っています。ASPEN試験やALPINE試験を含むいくつかの重要な臨床試験において、ブルキンサは有効であるだけでなく、競合薬よりも忍容性が高いことが示されています。例えば、ALPINE試験では、ブルキンサは再発または難治性のCLL患者において、イブルチニブと比較して優れた全奏効率と有意に少ない心臓の副作用を示しました。ブルキンサは、このような説得力のある結果を受けて、米国食品医薬品局（FDA）から様々な適応症で早期承認を取得し、有望ながん治療薬の審査プロセスを迅速化するFDAのReal-Time Oncology Review（RTOR）およびProject Orbisプログラムの下で継続的な評価を受けています。同様に、欧州連合（EU）と中国の規制当局もブルキンサの可能性を認めており、ベイジーン社はより広範な国際的患者層へのアクセスを拡大することができます。今回の承認は、単一の血液がんに限定されたものではなく、複数のB細胞悪性腫瘍にまたがるものであり、この薬剤の汎用性と市場シェアを高めるものです。ブルキンサは、奏効期間や無増悪生存期間を含む主要な臨床エンドポイントを満たす、あるいは上回る能力を有しており、治療プロトコールにおける役割は拡大しています。これらの結果は、保険会社による償還の決定や処方への組み入れにますます影響を与えるようになっており、世界中のヘルスケアシステムでの商業的な採用をさらに後押ししています。多様な患者集団や地域にわたる臨床データの一貫性は、標的がん治療における世界スタンダードとしての地位を強化しています。

ブルキンサの商業的成功を支える市場・業界動向は？

いくつかの重要な市場力学と業界力学が、がん治療領域におけるブルキンサの力強い商業的軌道を支えています。第一に、がん領域における標的治療への世界のシフトは、従来の化学療法レジメンよりも優れた有効性と安全性を提供するブルキンサのような精密医薬品にとって有利な環境を作り出しています。医師も患者も同様に、生存期間の延長だけでなく、特にCLLのような長期間の治療を必要とする慢性疾患において、QOLの改善にもつながる治療法を求めています。第二に、人口の高齢化と診断能力の向上による血液悪性腫瘍の有病率の増加が、対処可能な市場を拡大しています。加えて、戦略的パートナーシップや米国、欧州、アジアの主要市場への市場参入を含む積極的な商業化戦略により、地理的浸透が加速しています。同社は研究、製造、流通を自社で行う垂直統合型モデルにより、コストとサプライチェーンの面で優位に立っています。さらに、支払者やヘルスケアシステムは、臨床的価値の高い新規のがん治療薬への償還を受け入れつつあり、これはブルキンサの取り込みにとって良い兆しです。ブルキンサは、現在も適応拡大中であり、辺縁帯リンパ腫や濾胞性リンパ腫などの新たな適応症での臨床試験により、その商業的可能性はさらに高まっています。BTK阻害剤の競争が激化する中、ブルキンサの安全性、忍容性、実使用成績に基づく差別化は、市場優位性の礎であり続けると思われます。これらの動向が相まって、ブルキンサの強固な成長経路が確立され、拡大するがん治療薬市場での地位が強化されつつあります。

ブルキンサの普及と市場浸透の主な促進要因は？

ブルキンサ市場の成長は、臨床的、商業的、戦略的に相互に関連したいくつかの要因によって牽引されています。その中でも最も重要なのは、その優れた安全性と忍容性プロファイルであり、長期的な服薬アドヒアランスが不可欠な初回治療と再発・難治性治療の両方において重要であることが証明されています。前世代のBTK阻害剤で見られた一般的な副作用を軽減することが実証され、血液専門医の処方決定に大きな影響を与えています。もう一つの重要な推進力は、CLL、MCL、WMなどのB細胞性悪性腫瘍の罹患率が上昇していることであり、これらは人口の高齢化と世界の発見方法の改善により増加しています。この動向は、BTK阻害剤の対象となる患者層を拡大し、ブルキンサの採用の裾野を広げることになります。優先審査、ファスト・トラック指定、国際的な承認など、規制当局の機運は市場投入までの時間を早め、より広範な地理的アクセスを容易にしています。保険償還の獲得や国の治療ガイドラインへの組み入れも、特に保険適用が治療法の選択を左右する制度において、より迅速な採用を可能にしています。BeiGene社の戦略的投資により、営業力の拡大、医師との直接的な関わり、教育イニシアティブが効果的に行われ、がん医療従事者の間でブルキンサの認知度と受容度が高まっています。さらに、ブルキンサの併用療法や新規の適応症について現在進行中の臨床試験が、さらなる市場の可能性を引き出す態勢を整えています。個別化医療が牽引し続ける中、ブルキンサの標的を絞り、忍容性があり、効果的な結果をもたらす能力は、現代のがん医療においてますます中心的な役割を果たすことを確実にしています。これらの多面的な推進力により、ブルキンサは血液がん治療における革新的なソリューションとして、世界中で高い評価を得ています。

セグメント

疾患タイプ（急性リンパ性白血病,慢性リンパ性白血病）;エンドユーザー（病院エンドユーザー,クリニックエンドユーザー,その他エンドユーザー）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • InnoCare Pharma
  • Janssen Pharmaceuticals（J&J）
  • Lilly Asia Ventures
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pharmacyclics LLC（an AbbVie Co.）
  • Sanofi S.A.
  • Seagen Inc.
  • TG Therapeutics
  • Xynomic Pharmaceuticals

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38586

Global Brukinsa Market to Reach US$776.8 Million by 2030

The global market for Brukinsa estimated at US$615.9 Million in the year 2024, is expected to reach US$776.8 Million by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Acute Lymphocytic Leukemia, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$516.7 Million by the end of the analysis period. Growth in the Chronic Lymphocytic Leukemia segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$167.8 Million While China is Forecast to Grow at 7.1% CAGR

The Brukinsa market in the U.S. is estimated at US$167.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$156.5 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Brukinsa Market - Key Trends & Drivers Summarized

Why Has Brukinsa Become a Game-Changer in the Treatment of Hematologic Malignancies?

Brukinsa, a next-generation Bruton's tyrosine kinase (BTK) inhibitor developed by BeiGene, has rapidly emerged as a pivotal therapy in the landscape of hematologic cancers, particularly for patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenstrom’s macroglobulinemia (WM). Its high selectivity for BTK and ability to effectively inhibit B-cell receptor signaling pathways make it a critical weapon against B-cell malignancies. What sets Brukinsa apart is its favorable pharmacokinetic profile, marked by increased target occupancy and improved tissue penetration, which leads to enhanced efficacy and fewer off-target side effects compared to earlier BTK inhibitors like ibrutinib. It also demonstrates a lower incidence of treatment-limiting adverse events such as atrial fibrillation and bleeding, which makes it more tolerable, especially for elderly or high-risk patients. Brukinsa has gained multiple regulatory approvals in the United States, China, and the European Union based on strong clinical trial outcomes, including higher response rates and improved progression-free survival in relapsed or refractory patients. As more data continues to emerge from head-to-head comparison trials, its role in frontline treatment is also gaining attention. The growing recognition of Brukinsa's value by oncologists and its inclusion in various clinical guidelines underscore its importance in redefining standard-of-care practices for a range of blood cancers where targeted therapies are rapidly replacing conventional chemotherapy.

How Are Clinical Trial Outcomes and Regulatory Approvals Driving Brukinsa’s Global Expansion?

The clinical success of Brukinsa has been instrumental in securing widespread regulatory approvals and positioning the drug as a frontrunner in the BTK inhibitor market. Several pivotal clinical trials, including the ASPEN and ALPINE studies, have shown Brukinsa to be not only effective but also better tolerated than its competitors. In the ALPINE trial, for instance, Brukinsa demonstrated superior overall response rates and significantly fewer cardiac side effects compared to ibrutinib in patients with relapsed or refractory CLL. These compelling results led to Brukinsa receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for various indications, with continued evaluation under the agency’s Real-Time Oncology Review (RTOR) and Project Orbis programs, which expedite the review process for promising cancer therapies. Similarly, regulatory bodies in the European Union and China have recognized the potential of Brukinsa, enabling BeiGene to expand access to a broader international patient base. The approvals are not limited to a single type of blood cancer, but span multiple B-cell malignancies, enhancing the drug’s versatility and market footprint. The ability of Brukinsa to meet or exceed key clinical endpoints, including duration of response and progression-free survival, has earned it an expanding role in treatment protocols. These outcomes are increasingly influencing reimbursement decisions by insurers and inclusion in formularies, further supporting its commercial adoption across healthcare systems worldwide. The consistency of clinical data across diverse patient populations and geographical regions strengthens its case as a global standard in targeted oncology treatment.

What Market and Industry Trends Are Supporting the Commercial Success of Brukinsa?

Several key market and industry dynamics are converging to support the strong commercial trajectory of Brukinsa in the oncology therapeutics space. First, the global shift toward targeted therapies in oncology is creating a favorable environment for precision medicines like Brukinsa that offer superior efficacy and safety over traditional chemotherapeutic regimens. Physicians and patients alike are seeking treatment options that not only prolong survival but also offer improved quality of life, especially in chronic conditions like CLL that require long-term therapy. Second, the increasing prevalence of hematologic malignancies due to aging populations and improved diagnostic capabilities is expanding the addressable market. In addition, BeiGene’s aggressive commercialization strategy, including strategic partnerships and market entry into the U.S., Europe, and key Asian markets, has allowed for accelerated geographic penetration. The company’s vertically integrated model, with in-house research, manufacturing, and distribution capabilities, gives it cost and supply chain advantages. Moreover, payers and healthcare systems are becoming more receptive to reimbursing novel oncology therapies with strong clinical value, which bodes well for Brukinsa’s uptake. The drug’s ongoing label expansions and trials in new indications, such as marginal zone lymphoma and follicular lymphoma, further enhance its commercial potential. As competition in the BTK inhibitor space intensifies, Brukinsa’s differentiation based on safety, tolerability, and real-world performance will remain a cornerstone of its market advantage. These combined trends are establishing a robust growth pathway for Brukinsa, reinforcing its place in the expanding oncology therapeutics market.

What Are the Core Drivers Behind Brukinsa’s Rising Adoption and Market Penetration?

The growth in the Brukinsa market is driven by several interconnected clinical, commercial, and strategic factors. Foremost among these is its superior safety and tolerability profile, which is proving critical in both first-line and relapsed or refractory treatment settings where long-term adherence is essential. Its demonstrated ability to reduce common side effects seen with earlier-generation BTK inhibitors is significantly influencing prescribing decisions among hematologists. Another key driver is the rising incidence of B-cell malignancies, such as CLL, MCL, and WM, which are increasing due to aging populations and improved detection practices globally. This trend is expanding the eligible patient population for BTK inhibitors, providing a wider base for Brukinsa adoption. Regulatory momentum, including priority reviews, fast-track designations, and international approvals, is accelerating time-to-market and facilitating broader geographic access. Reimbursement wins and inclusion in national treatment guidelines are also enabling faster adoption, particularly in systems where coverage determines therapeutic choices. BeiGene’s strategic investments in sales force expansion, direct physician engagement, and education initiatives have effectively raised awareness and acceptance of Brukinsa among oncology care providers. Additionally, ongoing clinical trials exploring Brukinsa in combination therapies or in novel indications are poised to unlock further market potential. As personalized medicine continues to gain traction, Brukinsa’s ability to deliver targeted, tolerable, and effective outcomes is ensuring it plays an increasingly central role in modern oncology care. These multifaceted drivers are collectively cementing Brukinsa’s reputation as a transformative solution in hematologic cancer treatment worldwide.

SCOPE OF STUDY:

The report analyzes the Brukinsa market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia); End-User (Hospitals End-User, Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • InnoCare Pharma
  • Janssen Pharmaceuticals (J&J)
  • Lilly Asia Ventures
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pharmacyclics LLC (an AbbVie Co.)
  • Sanofi S.A.
  • Seagen Inc.
  • TG Therapeutics
  • Xynomic Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Brukinsa - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of B-Cell Malignancies Throws the Spotlight on Brukinsa as a Targeted Therapy Option
    • Here's the Story: How Brukinsa's Selectivity and Tolerability Differentiate It in the BTK Inhibitor Class
    • Expansion of Approved Indications Strengthens Business Case for Wider Adoption Across Hematologic Cancers
    • Growing Use in Treatment-Naive and Relapsed / Refractory Settings Expands Addressable Patient Population
    • Increasing Physician Familiarity and Prescribing Comfort Drives Uptake in Competitive Oncology Markets
    • Rising Demand for Oral Oncologics Supports Continued Momentum in Patient-Centered Treatment Models
    • Growing Head-to-Head Data Against Ibrutinib Throws the Spotlight on Brukinsa's Potential for Market Share Gains
    • Emerging Use in Combination Regimens Generates New Opportunities in Frontline and Maintenance Therapies
    • Increased Adoption in Community Oncology Settings Sustains Prescription Growth Outside Academic Centers
    • Competitive Pressures from Next-Generation BTK Inhibitors Create Urgency for Continued Label Expansion and Differentiation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Brukinsa Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Brukinsa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Brukinsa by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Brukinsa by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Brukinsa by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Brukinsa by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION